tbuckley/cabot-search huggingface dataset:
BCP-ALL blasts are not dependent on CD19 expression for leukaemic maintenance
Authors: J Weiland, D Pal, M Case, J Irving, F Ponthan, S Koschmieder, O Heidenreich, A von Stackelberg, C Eckert, J Vormoor, A Elder
Journal: Leukemia (2016)

In recent years the anti-CD19/anti-CD3 bispecific antibody blinatumomab and chimeric antigen receptor (CAR) modified T cells targeting CD19 have shown early efficacy in clinical trials of paediatric and adult B-cell precursor acute lymphoblastic leukaemia (BCP-ALL).1, 2, 3, 4, 5 The rationale behind targeting CD19 in BCP-ALL is primarily its homogenous cell surface expression and B-lineage specificity.5 Thus, the entire malignant cell population should be targeted and eradicated by anti-CD19-directed immunotherapies. CD19 would be expected to have important functions in BCP-ALL survival, based on its roles in enhancing pre-B-cell receptor (pre-BCR) mediated phosphoinositide 3-kinase (PI3K) signalling and through pre-BCR-independent pathways such as MYC activation.6, 7, 8, 9 However, the effects of CD19 depletion on BCP-ALL cells have not been investigated. Hence, we examined the role of CD19 in leukaemic maintenance by silencing its expression in BCP-ALL cell lines and primograft samples using RNA interference.
Primary care in accident and emergency departments
Authors: J. Fothergill, R Touquet, P Ward
Journal: BMJ (1995)

Outcomes of study cast doubt on sensitivity of triage decisions and triage criteria

EDITOR,--Jeremy Dale and colleagues highlight the difficult and unresolved problem of appropriate triage for patients attending accident and emergency departments with “primary care” type problems.1 We have had a primary care service in our accident and emergency department since February 1993, which we recently analysed.2

At St Mary's …
Birth Characteristics of Children Dying of Malignant Neoplasms&lt;xref ref-type="fn" rid="fn1"&gt;2&lt;/xref&gt;
Authors: Brian MacMahon, M.D., Vaun A. Newill, M.D.
Journal: JNCI Journal of the National Cancer Institute (1962)

Through review of certificates of death and birth, we have identified 4,198 children who were born between 1947 and 1954 in any of the New England or Middle Atlantic States and who died at some time between 1947 and 1958 of malignant disease. Data from the birth certificates of these children have been compared with similar data on all live births in the same region during the same years and with data from certificates of a comparison series. Mortality from leukemia was associated both with birth order and with maternal age, risk of death being about 50 percent higher in first than in fifth and later births, and about 40 percent higher in children of women over 40 years of age than in those of women under 20 years of age. These associations were independent. No other form of neoplasm showed a significant association with either maternal age or parity. No association of mortality from leukemia or other neoplasm with birth weight or number of prior stillbirths was found. Twins were not unduly represented in the series. The series contained one instance of a set of twins, both of whom died of leukemia.
Multiple-serotype Salmonella gastroenteritis outbreak after a reception - Connecticut, 2009.
Authors: L. Mank, M. Mandour, T. Rabatsky-Ehr, Q. Phan, J. Krasnitski, J. Brockmeyer, L. Bushnell, C. Applewhite, M. Cartter, J. Kattan
Journal: MMWR Morbidity and Mortality Weekly Report (2010)
The Evolving Approach to Brain Dysfunction in Critically Ill Patients
Authors: E. Wesley Ely, Pratik P. Pandharipande
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy
Authors: Simone M. Goldinger, Pascale Stieger, Barbara Meier, Sara Micaletto, Emmanuel Contassot, Lars E. French, Reinhard Dummer
Journal: Clinical Cancer Research (2016)

Immunotherapy has experienced impressive progress in cancer treatment. Antibodies against PD-1 improved survival in different types of cancer including melanoma. They are generally well tolerated. However, skin toxicities including pruritus, rashes, and vitiligo are reported. Although frequent, they have not been characterized further yet. In this analysis, we aimed to systematically assess and characterize the adverse cutaneous reactions observed in patients with melanoma treated with anti-PD-1 antibodies.Patients with melanoma were treated with anti-PD-1 antibodies within clinical trials and an early-access program. Adverse cutaneous eruptions that emerged in our melanoma patient cohort were systematically investigated and classified using histology and gene expression profiling in comparison with maculopapular drug rash, cutaneous GVHD, and the severe drug eruption toxic epidermal necrolysis (TEN).Between February 2013 and September 2015, 68 patients with stage IV melanoma were treated at the University Hospital Zurich (Zurich, Switzerland); 15 patients (22%) developed cutaneous reactions and 10 (15%) vitiligo. The cutaneous reactions ranged from small erythematous papules with mild pruritus to disseminated erythematous maculopapular rashes (MPR) without signs of epidermal involvement to severe MPRs, including epidermal detachment and mucosal involvement. Although skin involvement varied from mild rash to bullous drug eruptions, gene expression profiling pathogenically classified all investigated cases as TEN-like reactions.As predicted by the PD-1 knockout mouse, anti-PD-1 antibodies frequently cause adverse cutaneous reactions. Gene expression profiling reminds in all cases of a TEN-like pattern, suggesting that PD-1/PD-L1 interaction is required to preserve epidermal integrity during inflammatory skin reactions. Clin Cancer Res; 22(16); 4023-9. ©2016 AACR.
Bone marrow transplantation as salvage therapy in advanced Hodgkin's disease: allogeneic or autologous.
Authors: G P Canellos
Journal: Journal of Clinical Oncology (1985)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1985.3.11.1451 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 3932604 Bone marrow transplantation as salvage therapy in advanced Hodgkin's disease: allogeneic or autologous. G P CanellosxG P CanellosSearch for articles by this author https://doi.org/10.1200/JCO.1985.3.11.1451 First Page PDF © 1985 by American Society of Clinical Oncology
Phase I clinical trial of MLN8054, a selective inhibitor of Aurora A kinase
Authors: S. F. Jones, R. B. Cohen, E. C. Dees, Y. Lee, J. A. Papas, M. R. Cooper, K. M. Galvin, H. A. Burris
Journal: Journal of Clinical Oncology (2007)

3577 Background: MLN8054 is a small molecule inhibitor of Aurora A kinase, with &gt; 150-fold greater potency against this enzyme than the structurally related but functionally distinct Aurora B kinase. Because of its structural similarity to benzodiazepines, MLN8054 binds to the gamma-aminobutryic acid alpha 1 benzodiazepine (GABA A a1 BZD) receptor and in preclinical studies caused benzodiazepine-like CNS effects. Methods: MLN8054 was given as capsule by mouth for 7 consecutive days, repeated every 21 days. Cohorts of 3- 6 patients (pts) were enrolled to successively increasing doses until dose-limiting toxicity was seen in = 2 pts at a given dose level. Serial blood samples were collected to estimate PK; skin biopsies were obtained before and 6 hours after the first dose to assess inhibition of Aurora A kinase in basal epithelial cells. Results: 22 pts were enrolled to evaluate single daily doses of 5, 10, 20, 30 and 40 mg/day. MLN8054 was in general rapidly absorbed, displayed dose-proportionate exposure, and had a mean elimination half-life of 35 hours. The ratio of peak to trough plasma concentrations was approximately 5. Reversible grade 2 somnolence was first seen in 3 patients treated at 20 mg/day, and 2/4 patients treated at 40 mg/day experienced reversible grade 3 somnolence. In order to reduce the sedative effects of MLN8054, 16 additional pts were enrolled to doses of 25, 35, 45 and 55 mg/day given as divided doses on a QID schedule. Two of 4 pts treated at the 55 mg/day dose experienced reversible grade 3 somnolence, establishing 45 mg/day as the maximum tolerated total daily dose on a QID schedule. No myelosuppression or mucosal toxicity was seen at any dose with either schedule. Immunohistochemical analysis of skin biopsies from pts treated with once daily dosing did not demonstrate accumulation of cells in mitosis. Three pts with metastatic colorectal cancer treated with single daily doses of MLN8054 received = 8 cycles of treatment. Conclusions: The study is now escalating divided daily dosing of MLN8054 with the co-administration of methylphenidate. Post-treatment skin biopsies are now obtained on Day 7. Duration of treatment will be extended to 14 days, since steady-state concentrations of MLN8054 require 5–7 days of dosing, and because the effects of Aurora A kinase inhibition are duration-dependent. No significant financial relationships to disclose.
Residual Neck Disease (Rnd) Management in Squamous-Cell Carcinoma of the Head and Neck (Scchn) Treated with Radiotherapy (Rt) Plus Cetuximab (C)
Authors: R. Montal, L. De Avila, M. Taberna, M. Oliva, A. Rovira, M. Cos, M. Mañós, V. Navarro, J. Nogués, A. Lozano, S. Vázquez, R. Mesia
Journal: Annals of Oncology (2014)
Prospective evaluation of neurotoxicity in breast cancer patients treated with adjuvant paclitaxel
Authors: M. G. Zauderer, K. D. Crew, L. H. Weimer, L. Brafman, D. Fuentes, A. Sierra, D. L. Hershman
Journal: Journal of Clinical Oncology (2008)

20567 Background: Taxanes are increasingly used in the treatment of early stage breast cancer (BC). Up to 30% of patients develop moderate-severe neurotoxicity during treatment. The prevalence, severity, and natural history of this syndrome have not been well described. Methods: Using a prospective cohort study design, women with stage I-III breast cancer undergoing adjuvant paclitaxel were enrolled. At baseline, 4 weeks, 8 weeks, 3 months, and 6 months, all patients completed the Functional Assessment of Cancer Therapy-Taxane (FACT-Tax) and quantitative sensory testing (touch perception and vibration threshold) was conducted. The FACT-Tax includes a 16-item subscale which measures the severity of neurotoxicity, where lower scores represent worsening symptoms. Blood was obtained at baseline and 2 weeks post-treatment to measure serum nerve growth factor (NGF) levels. Results: A total of 22 out of a target of 50 patients have been enrolled to date; median age: 51.5 (37–78); White/Black/Hispanic: 8/1/13; median BMI kg/m2: 27 (21–44); stage I/II/III: 4/13/5; paclitaxel regimen T q2wks x4/T q2wks x6/T qwk x12: 13/7/2. Compared to baseline, there was a significant decrease in vibration sense at 4 weeks and 8 weeks during active treatment. Mean scores on the Neurotoxicity subscale of the FACT-Tax decreased from 37.2 at baseline to 30.5 at week 4 (p=0.001) and 29.3 at week 8 (p=0.001). These scores remained low 3 months and 6 months after completing paclitaxel treatment (32.0 and 28.6, respectively). At 6 months, 50–60% of patients reported persistent numbness or discomfort in the hands and feet. Serum NGF analyses are underway to determine whether this biomarker correlates with neuropathy symptoms. Conclusions: To our knowledge, this is the first study to prospectively evaluate persistent neuropathy in women receiving adjuvant paclitaxel. Over 50% of patients developed moderate to severe neuropathy during active treatment, which persisted 6 months post-treatment. Taxane-based chemotherapy has been shown to improve survival, however, neurotoxicity is the main dose-limiting side effect. Understanding the natural history of this toxicity and validating appropriate measures to be used in interventions to prevent and treat taxane-induced neuropathy are critical. No significant financial relationships to disclose.
Plasma Fibrinogen Qualification as a Drug Development Tool in Chronic Obstructive Pulmonary Disease. Perspective of the Chronic Obstructive Pulmonary Disease Biomarker Qualification Consortium
Authors: Bruce E. Miller, Ruth Tal-Singer, Stephen I. Rennard, Armin Furtwaengler, Nancy Leidy, Michael Lowings, Ubaldo J. Martin, Thomas R. Martin, Debora D. Merrill, Jeffrey Snyder, John Walsh, David M. Mannino
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

Section:ChooseTop of pageAbstract <<Drug Development and the ...The COPD Biomarker Qualif...Plasma Fibrinogen as a Bi...ImplicationsConclusions and Next Step...ReferencesCITING ARTICLES
Influence of Nonsteroid Anti-Inflammatory Agents on Protein Synthesis and Hyperplasia Caused by a Tumor Promoter2
Authors: John D. Scribner, Thomas J. Siaga
Journal: JNCI Journal of the National Cancer Institute (1974)

Journal Article Influence of Nonsteroid Anti-Inflammatory Agents on Protein Synthesis and Hyperplasia Caused by a Tumor Promoter Get access John D. Scribner, John D. Scribner Search for other works by this author on: Oxford Academic PubMed Google Scholar Thomas J. Siaga Thomas J. Siaga Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 52, Issue 6, June 1974, Pages 1865–1868, https://doi.org/10.1093/jnci/52.6.1865 Published: 01 June 1974 Article history Received: 03 January 1974 Accepted: 15 March 1974 Published: 01 June 1974
Building and Strengthening Infection Control Strategies to Prevent Tuberculosis — Nigeria, 2015
Authors: E. Kainne Dokubo, Bethrand Odume, Virginia Lipke, Custodio Muianga, Eugene Onu, Ayodotun Olutola, Lucy Ukachukwu, Patricia Igweike, Nneka Chukwura, Emperor Ubochioma, Everistus Aniaku, Chinyere Ezeudu, Joseph Agboeze, Gabriel Iroh, Elvina Orji, Okezue Godwin, Hasiya Bello Raji, S.A. Aboje, Chijioke Osakwe, Henry Debem, Mustapha Bello, Dennis Onotu, Susan Maloney
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

Tuberculosis (TB) is the leading cause of infectious disease mortality worldwide, accounting for more than 1.5 million deaths in 2014, and is the leading cause of death among persons living with human immunodeficiency virus (HIV) infection (1). Nigeria has the fourth highest annual number of TB cases among countries, with an estimated incidence of 322 per 100,000 population (1), and the second highest prevalence of HIV infection, with 3.4 million infected persons (2). In 2014, 100,000 incident TB cases and 78,000 TB deaths occurred among persons living with HIV infection in Nigeria (1). Nosocomial transmission is a significant source of TB infection in resource-limited settings (3), and persons with HIV infection and health care workers are at increased risk for TB infection because of their routine exposure to patients with TB in health care facilities (3-5). A lack of TB infection control in health care settings has resulted in outbreaks of TB and drug-resistant TB among patients and health care workers, leading to excess morbidity and mortality. In March 2015, in collaboration with the Nigeria Ministry of Health (MoH), CDC implemented a pilot initiative, aimed at increasing health care worker knowledge about TB infection control, assessing infection control measures in health facilities, and developing plans to address identified gaps. The approach resulted in substantial improvements in TB infection control practices at seven selected facilities, and scale-up of these measures across other facilities might lead to a reduction in TB transmission in Nigeria and globally.
Manual vs. automated analysis of polysomnographic recordings in patients with COPD
Authors: Gerben Stege, Petra J.E. Vos, P.N. Richard Dekhuijzen, Pieter H.E. Hilkens, Marjo J.T. van de Ven, Yvonne Heijdra, Frank J.J. van den Elshout
Journal: European Respiratory Journal (2011)

Background:  Manual analysis of polysomnography (PSG) is time-consuming and computer systems have been developed to automatically analyse PSGs. Studies on the reliability of automated analyses in healthy subjects show varying results. In patients with Chronic Obstructive Pulmonary Disease (COPD) these studies have not been performed, while sleep quality can severely be disturbed in these patients. It is unknown whether automated analysis of PSG in patients with COPD provide accurate outcomes.   Methods:  In a retrospective study the full-night polysomnographic recordings of patients with and without COPD were analysed manually and automatically. The outcomes of manual and automated analyses in both groups were compared using Bland-Altman plots, Students9 paired t-tests, and Pearson9s correlation coefficients.   Results:  50 PSGs from patients with COPD and 57 PSGs from patients without COPD were included. In both study groups agreement between manual and automatic analyses was poor in nearly all sleep and respiratory parameters, like the total sleep time, sleep efficiency, sleep latency, amount of REM sleep, no. of arousals, and the apnoea-hypopnoea-index.   Conclusion:  Automatic analysis of PSGs in patients with COPD have poor agreement with manual analysis when looking at sleep and respiratory parameters and should therefore not replace the manual analysis of PSG recordings in patients with COPD.
Inherited GATA3 genetic Variants Are Associated With Childhood BCR-ABL1-Like Acute Lymphoblastic Leukemia and Increased Risk Of Relapse
Authors: Kathryn G. Roberts, Richard C. Harvey, Wenjian Yang, Cheng Cheng, Deqing Pei, Heng Xu, Julie Gastier-Fostier, Shuyu E, Joshua Yew-Suang Lim, I-Ming L. Chen, Yiping Fan, Meenakshi Devidas, Michael J. Borowitz, Colton Smith, Geoffrey A. Neale, Esteban Gonzalez Burchard, Dara G Torgerson, Federico Antillon, Cesar Rolando, Naomi J. Winick, Bruce Camitta, Elizabeth A. Raetz, Brent L. Wood, Feng Yue, William L. Carroll, Eric C. Larsen, William Paul Bowman, Mignon L. Loh, Michael Dean, Deepa Bhojwani, Ching-Hon Pui, William E. Evans, Mary V. Relling, Stephen P. Hunger, Cheryl L. Willman, Charles G. Mullighan, Frcpa, Jun J. Yang
Journal: Blood (2013)
<i>In vitro</i>tests for drug hypersensitivity reactions: an<scp>ENDA</scp>/<scp>EAACI</scp>Drug Allergy Interest Group position paper
Authors: C. Mayorga, G. Celik, P. Rouzaire, P. Whitaker, P. Bonadonna, J. Rodrigues‐Cernadas, A. Vultaggio, K. Brockow, J. C. Caubet, J. Makowska, A. Nakonechna, A. Romano, M. I. Montañez, J. J. Laguna, G. Zanoni, J. L. Gueant, H. Oude Elberink, J. Fernandez, S. Viel, P. Demoly, M. J. Torres
Journal: Allergy (2016)

Drug hypersensitivity reactions (DHRs) are a matter of great concern, both for outpatient and in hospital care. The evaluation of these patients is complex, because in vivo tests have a suboptimal sensitivity and can be time-consuming, expensive and potentially risky, especially drug provocation tests. There are several currently available in vitro methods that can be classified into two main groups: those that help to characterize the active phase of the reaction and those that help to identify the culprit drug. The utility of these in vitro methods depends on the mechanisms involved, meaning that they cannot be used for the evaluation of all types of DHRs. Moreover, their effectiveness has not been defined by a consensus agreement between experts in the field. Thus, the European Network on Drug Allergy and Drug Allergy Interest Group of the European Academy of Allergy and Clinical Immunology has organized a task force to provide data and recommendations regarding the available in vitro methods for DHR diagnosis. We have found that although there are many in vitro tests, few of them can be given a recommendation of grade B or above mainly because there is a lack of well-controlled studies, most information comes from small studies with few subjects and results are not always confirmed in later studies. Therefore, it is necessary to validate the currently available in vitro tests in a large series of well-characterized patients with DHR and to develop new tests for diagnosis.
The favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma
Authors: Giorgio La Nasa, Marianna Greco, Roberto Littera, Sara Oppi, Ivana Celeghini, Rossella Caria, Sara Lai, Rita Porcella, Massimo Martino, Alessandra Romano, Francesco Di Raimondo, Andrea Gallamini, Carlo Carcassi, Giovanni Caocci
Journal: Journal of Hematology & Oncology (2016)

Interim positron emission tomography after 2 cycles of ABVD (iPET-2) is a good predictor of outcome in advanced-stage classic Hodgkin lymphoma. So far, there are no other prognostic biomarkers capable of identifying chemotherapy refractory patients with comparable accuracy. Despite the considerable amount of evidence suggesting that antitumor immune surveillance is downregulated in classic Hodgkin lymphoma (cHL), few data exist on the impairment of natural killer cell function and the role of their killer immunoglobulin-like receptors (KIRs). We investigated KIR gene frequencies, KIR haplotypes, and KIR-ligand combinations in a cohort of 135 patients with advanced-stage classic Hodgkin lymphoma and 221 healthy controls. We furthermore evaluated the correlation of KIR genes and KIR haplotypes with the achievement of negative iPET-2. In the cohort of patients, the 5-year overall survival and progression-free survival were 93.6 and 79 %, respectively. Homozygosity for KIR A haplotype and the HLA-C1 KIR ligand (KIR-AA/C1C1) was significantly higher in healthy controls (15.7 vs. 4.8 %, p = 0.001). The KIR-AA genotype resulted to have a significant predictive power for achieving iPET-2 negativity (p = 0.039). Homozygosity for KIR A haplotype offers protection against classic Hodgkin lymphoma. The association found for the KIR-AA genotype and achievement of negative iPET-2 suggests that KIR-AA could be used in clinical practice to enhance the chemosensitivity predictive power of iPET-2. Our results point to the possibility of adapting treatment strategies based on the combination of KIR biomarkers and PET scan.
Failure of Immunosurveillance Against Chemically Induced In Situ Tumors in Mice 2
Authors: Edwin J. Andrews
Journal: JNCI Journal of the National Cancer Institute (1974)

Journal Article Failure of Immunosurveillance Against Chemically Induced In Situ Tumors in Mice Get access Edwin J. Andrews Edwin J. Andrews 3Department of Comparative Medicine, The Pennsylvania State University, The Milton S. Hershey Medical Center, College of Medicine, Hershey, Pa. 17033. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 52, Issue 3, March 1974, Pages 729–732, https://doi.org/10.1093/jnci/52.3.729 Published: 01 March 1974 Article history Received: 09 July 1973 Accepted: 31 October 1973 Published: 01 March 1974